Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MJT.0000000000000457 | DOI Listing |
Traffic Inj Prev
January 2025
School of Traffic & Transportation Engineering, Changsha University of Science & Technology, Changsha, Hunan, China.
Objective: This study aims to investigate the causes of 2-vehicle collisions involving an autonomous vehicle (AV) and a conventional vehicle (CV). Prior research has primarily focused on the causes of crashes from the perspective of AVs, often neglecting the interactions with CVs.
Method: To address this limitation, the study proposes a classification framework for crash causation patterns in 2-vehicle collisions involving an AV and a CV, considering their interactions.
Trials
December 2024
School of Public Health, University of Michigan, 1420 Washington Heights, Ann Arbor, MI, USA.
Current guidelines tend to focus on a p-value threshold of a pre-specified primary endpoint tested in randomized controlled clinical trials to determine a treatment effect for a specific drug. However, a p-value does not always provide evidence on the treatment effect of a drug, especially when stratification of the data does not account for unforeseen variables introduced into the analysis. We report and discuss a rare case in which investigational site stratification in the pre-specified analysis method of a primary endpoint results in a loss of statistical power in the evaluation of the treatment effect due to data attrition of almost 17% of outcome data in the phase III randomized, controlled PANAMO study in critically ill COVID-19 patients.
View Article and Find Full Text PDFJ Pak Med Assoc
November 2024
Department of Paediatrics, Dr. Ziauddin Hospital, Karachi, Pakistan.
Colorectal cancer (CRC) cells express sialylated Lewis antigens (sLe), crucial for metastasis via E-selectin binding. However, these glycoepitopes lack cancer specificity, and E-selectin-targeted glycoproteins remain largely unknown. Here, we established a framework for identifying metastasis-linked glycoproteoforms.
View Article and Find Full Text PDFFront Oncol
October 2024
Pharmacy Department, Baotou Cancer Hospital, Baotou, China.
Introduction: The advent of bevacizumab has considerably transformed the therapeutic landscape for non-small cell lung cancer (NSCLC) patients devoid of specific genetic mutations. A pivotal milestone has been reached with the recent approval of a bevacizumab biosimilar, following rigorous phase III clinical investigations, poised to augment NSCLC therapeutic strategies.
Methods: This retrospective analysis encompasses a large-scale study conducted between January 2021 and December 2023, involving 1058 NSCLC patients (metastatic or locally advanced stages).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!